| Aug 6 |
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
|
| Aug 6 |
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
|
| Aug 5 |
Sangamo Therapeutics Q2 2024 Earnings Preview
|
| Jul 30 |
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
|
| Jul 26 |
Sangamo rallies for third day in wake of positive gene therapy results
|
| Jul 25 |
Peering Into Sangamo Therapeutics's Recent Short Interest
|
| Jul 24 |
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
|
| Jul 24 |
Pfizer/ Sangamo gene therapy for hemophilia A succeeds in late-stage trial
|
| Jul 24 |
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
|
| Jul 23 |
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
|
